Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC

NCT04887506 is registered in ClinicalTrials.gov with Tavanta Therapeutics as lead sponsor.

NCT NCT04887506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04887506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Lead sponsor
Tavanta Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 5, 2021
Completion date
October 20, 2022
Enrollment
107 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, metastatic prostate cancer